Leading the way for
pediatric behavioral health.
We are developing digital diagnostics and therapeutics with the goal of enabling earlier and more equitable care for behavioral health conditions.
We’re excited to announce that the FDA has granted marketing authorization for Cognoa’s autism diagnosis aid.
Behavioral Health Solutions for
Earlier Diagnosis and Care
Cognoa is committed to developing products for earlier diagnosis and treatment, with the goal of improving lifelong outcomes for children and families.
Our lead products aim to enable earlier and more equitable treatment of behavioral health conditions.
We seek to empower parents to make a positive impact on their child’s development during critical intervention windows.
Join our diverse team with opportunities spanning product, engineering, data science, and clinical.
FDA Breakthrough designation products
Cognoa has received Breakthrough Device Designation from the FDA for both its lead products, a digital diagnostic and therapeutic for autism.
Early Intervention Lasts a Lifetime
When children have access to treatments during early childhood, they have the best opportunity to reach their full potential in life. When they don’t, treatments are likely to be less impactful, children and families suffer, and it’s more costly for our healthcare system and communities.